Güncel Patoloji Dergisi
2022, Cilt 6, Sayı 1
ROS1 Rearrangement in Non-Small Cell Lung Cancer: Attitude towards ROS1 Test in Turkey
1 Gazi Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı, ANKARA
2 Cerrahpaşa Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı, İSTANBUL
3 Marmara Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı, İSTANBUL
4 Ege Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı, İZMIR
5 Karadeniz Teknik Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı, TRABZON
6 Çukurova Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı, ADANA
DOI : 10.5146/jcpath.2022.73 Lung cancer is the most common type of cancer and the leading cause of cancer deaths in Turkey and the world. Recently, increasing number of non-small cell lung cancer (NSCLC)-related genomic and immunohistochemical biomarkers has been identified. The ROS1 kinase (ROS1) is an oncogenic driver and observed in approximately 1- 2% of patients with NSCLC. Identification of ROS1 rearrangement is mandatory to permit targeted therapy with specific inhibitors, demonstrating a significantly better survival when compared with conventional chemotherapy. This review is a discussion on the present and futuristic diagnostic methods of ROS1 identification and ROS1-targeted therapies in lung cancer. Anahtar Kelimeler : Non-small cell lung cancer, ROS1, Gene rearrangement, Molecular-targeted therapies
2 Cerrahpaşa Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı, İSTANBUL
3 Marmara Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı, İSTANBUL
4 Ege Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı, İZMIR
5 Karadeniz Teknik Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı, TRABZON
6 Çukurova Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı, ADANA
DOI : 10.5146/jcpath.2022.73 Lung cancer is the most common type of cancer and the leading cause of cancer deaths in Turkey and the world. Recently, increasing number of non-small cell lung cancer (NSCLC)-related genomic and immunohistochemical biomarkers has been identified. The ROS1 kinase (ROS1) is an oncogenic driver and observed in approximately 1- 2% of patients with NSCLC. Identification of ROS1 rearrangement is mandatory to permit targeted therapy with specific inhibitors, demonstrating a significantly better survival when compared with conventional chemotherapy. This review is a discussion on the present and futuristic diagnostic methods of ROS1 identification and ROS1-targeted therapies in lung cancer. Anahtar Kelimeler : Non-small cell lung cancer, ROS1, Gene rearrangement, Molecular-targeted therapies